[The role of pathogenetic therapy in preserving ejaculate fertility in patients with tuberculosis of prostate].

Introduction: Genital tuberculosis impairs male reproductive function. Given that tuberculosis of the prostate has been found at autopsy in 77% of men who died of tuberculosis of all locations, the problem is highly relevant.
Aim: To develop and test a method of restoring/preserving fertility in patients with prostatic tuberculosis and to evaluate its effectiveness.
Material and Methods: TThis is an open, prospective, comparative, randomized study, comprising 72 patients with prostatic tuberculosis. Patients of the main group (n=49) received standard TB treatment in combination with pathogenetic spermatoprotective therapy including zinc and selenium based dietary supplement and chorionic gonadotropin. The men in the comparison group (n=23) were treated only with etiotropic TB therapy.
Results: TB treatment had a negative effect on the ejaculate: in the comparison group a two-month course of drug therapy resulted in a decrease in sperm cell count by 23.9%, in the number of actively motile sperm cells by 10.6% and in the number of normal sperm cells by 32.3%. Pathogenetic spermatoprotective therapy increased the sperm cell count by 47.8%, the number of active mobile forms of spermatozoa (total of A and B) by 40.5%, the number of normal sperm cells by 41.9%.
Conclusions: Spermatoprotective therapy, including human chorionic gonadotropin and zinc and selenium based dietary supplement significantly increases the ejaculate fertility.